Trial Profile

A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Cisplatin; Pemetrexed
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms TRAIL

Most Recent Events

13 Jul 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
20 Apr 2015 Status changed from recruiting to completed.
30 Jan 2013 Planned number of patients changed from 562 to 276 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com